Table IV.
Association between MAPK and EGFR expression, lymph node metastasis, and recurrence and metastasis in patients with TNBC.
| MAPK | EGFR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patients, n | Relative positive | Relative negative | χ2 value | P-value | Relative positive | Relative negative | χ2 value | P-value | ||
| Lymph node metastasis | Yes | 117 | 57 (48.7) | 60 (51.3) | 7.08 | 0.008 | 65 (55.6) | 52 (44.4) | 7.05 | 0.008 |
| No | 183 | 61 (33.3) | 122 (66.7) | 73 (39.9) | 110 (60.1) | |||||
| Clinical stage | I | 82 | 24 (29.3) | 58 (70.7) | 10.9 | 0.004 | 22 (26.8) | 60 (73.2) | 16.9 | 0.001 |
| II | 140 | 51 (36.4) | 89 (63.6) | 60 (42.9) | 80 (57.1) | |||||
| III | 78 | 42 (53.8) | 36 (46.2) | 46 (59.0) | 32 (41.0) | |||||
| Recurrence and metastasis | Yes | 85 | 46 (54.1) | 39 (45.9) | 10.86 | 0.001 | 52 (61.2) | 33 (38.8) | 12.01 | 0.001 |
| No | 215 | 72 (33.5) | 143 (66.5) | 84 (39.1) | 131 (60.9) | |||||
MAPK, mitogen-activated protein kinase; EGFR, epidermal growth factor receptor; TNBC, triple negative breast cancer. The percentage of the patient population is indicated in brackets.